A groundbreaking shift in our drug policy has taken place, as the regulators permit the availability of psilocybin hallucinogens for therapeutic purposes. Previously, these substances were heavily restricted, but a increasing body of evidence suggests they may offer aid for emotional illnesses like PTSD. The new policy represents a substantial step